Company intelligence / Profile preview

GDS ClinicalZest

Noida, Uttar Pradesh, India

Ownership: Private
Employees: ~100
Development stage: Other

Overview

GDS ClinicalZest is a global clinical research organization (CRO) and technology solutions provider dedicated to streamlining the clinical trial lifecycle. The company offers end-to-end services including patient recruitment, site monitoring, clinical data management, and pharmacovigilance. At the heart of its operations is the ClinicalZest platform, a proprietary technology designed to enhance trial efficiency through real-time data analytics and patient-centric engagement tools. GDS ClinicalZest partners with pharmaceutical and biotechnology companies to navigate complex regulatory landscapes and accelerate the delivery of innovative treatments. The firm is headquartered in India and maintains a strong focus on digital transformation within the life sciences sector.

Industry: Contract Research Organization

Beyond the preview

Go deeper on GDS ClinicalZest.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GDS ClinicalZest.

Explore the full profile